LMO2 as a Biomarker for Hypersensitivity to Genotoxic Therapy

In this issue of Cancer Cell, Parvin and colleagues identify the expression of LMO2 as a biomarker for DNA repair defects in lymphomas. Using isogenic cell lines and xenografts, the authors show that expression of LMO2 predicts sensitivity to PARP inhibition, especially in combination with genotoxic therapy.

from Cancer Cell https://ift.tt/30odwk4